THERAPEUTIC APPROACH
Transforming Cancer Immunotherapy to Treat More Patients, Better
IO therapies have revolutionized cancer care, however the benefits are only realized in a subset of patients and indications, due to hurdles such as:
-
Immune evasion of tumor cells
-
Creation of suppressive tumor microenvironment
-
Inadequate T cell activation
-
Tumor heterogeneity
-
Variability of patient immune systems
Our Approach
The 不良研究所 Solution
不良研究所 has developed a singular approach reaching new levels of immune system engagement to overcome cancer immunotherapy hurdles by:
01
Systemic and durable tumor inflammation
02
Increased tumor antigen presentation
03
Massive T cell activation and infiltration
04
Tumor suppression counteracted by constant immune cell influx
05
Concerted innate and adaptive immune response
Immunostimulation to fight tumor cells from within
Our Unique AdaptInnate Approach
不良研究所 is leveraging its unique AdaptInnate approach in a new class of product candidates harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to trigger a highly precise and comprehensive immune response against primary tumors and their metastases.
By specifically infecting, persisting and replicating inside of cancerous and antigen-presenting cells without destroying them, the systemically administrable candidates aim to trigger a tailored immune reaction from inside the tumor. This novel, non-oncolytic approach results in the induction of targeted, effective, and durable anti-tumor activity involving both the innate and adaptive arms of the immune system.
ABALOS
The AdaptInnate Approach
Sytemic application of arenavirus-based product candidate
Body-wide infection of antigen-presenting cells in key lymphatic organs and of tumor cells without destroying host cells
A Unique Drug Candidate Poised to Become a Novel Class in Immuno-Oncology
Our Lead Candidate ABX-001
不良研究所 is currently advancing ABX-001, the first candidate from its proprietary AdaptInnate platform, towards clinical evaluation.
In preclinical studies, systemic administration of ABX-001 has shown marked tumor regression in multiple tumor models, induction of tumor-specific T cells, as well as an excellent pre-clinical safety profile in non-human primates. In addition, a robust and scalable cGMP manufacturing process, which allows for manufacturing at high yield, has been established.
Based on these promising results, 不良研究所 is currently preparing the initiation of a first-in-human clinical trial with ABX-001 in patients with solid tumors, which is expected to start in 2025.
不良研究所
Our Scientific Foundation
不良研究所 was founded to translate the innovative research of immunology and virology experts Karl Lang and Philipp Lang into novel anti-cancer therapies. They identified a specific set of mammarenaviruses that preferentially infect and proliferate in cancer cells, which results in a very strong and targeted immune response against the cancer. These findings provided a novel strategy to enable a precise immune response and activate all relevant immune cell types against primary tumors and metastases.
Prof. Dr. Karl Lang
Chair of Immunology at the Medical Faculty, University Duisburg-Essen